This content is from: Premium European Activism Is in the Doldrums Shareholders are winning far fewer proxy battles this year. By Michelle Celarier November 25, 2019
This content is from: Premium Elliott Versus Greenlight, Round Two Why Elliott is all in on the shares of Bayer, which Greenlight unloaded in the first quarter. By Stephen Taub June 27, 2019
This content is from: Corner Office Merrill Isn’t Going Away, Says Bank of America As part of its rebranding effort, Bank of America is readying a Merrill campaign. By Alicia McElhaney February 26, 2019
This content is from: Portfolio Boardroom ‘Gut Check’ Set to Drive M&A Company boardrooms feel pressure to do deals to deliver growth to shareholders. By Dan Weil January 25, 2018
This content is from: Corner Office Why Initial Public Offerings Will Rebound in 2017 Last year volatile stock markets dampened IPOs. This year should be better – if markets behave. By Dan Weil February 13, 2017
This content is from: Culture How Wall Street Abetted an Opioid Disaster Insys Therapeutics allegedly pushed doctors to prescribe extreme pain medication for minor discomfort. People died. Wall Street analysts missed it — but a handful of journalists and hedge funds knew. By Jesse Barron September 05, 2018
Sponsored Stability Amidst Risk and Volatility Multi-asset risk mitigation strategies are in demand in trying times. Here’s why. Sponsored by Invesco July 28, 2020
Sponsored You Still Need to Strengthen Portfolio Resilience How COVID-19 will play out remains uncertain. Multi-asset strategies have the flexibility and potential to address risks as they evolve. Sponsored by Invesco July 28, 2020
